The content on this site is intended for healthcare professionals only
Women with breast cancer characterised by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented at the 2013 San Antonio Breast Cancer Symposium ( SABCS ).
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
ASCO 2023: Breast cancer research highlights
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
